Semperit (SEM) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
19 May, 2026Executive summary
Q1 2026 showed strong operational recovery, with momentum from H2 2025 and both divisions contributing to performance.
Revenue grew 7.9% year-on-year to EUR 163.7 million, EBITDA more than doubled to EUR 26.8 million, margin at 16.4%.
Results supported by strict pricing, cost discipline, innovation, and digital transformation initiatives.
Divisional earnings profile became more balanced, with SEA contributing 37% to group EBITDA, up from 26% in Q1 2025.
Earnings after tax improved to EUR 8.9 million from a loss of EUR -7.2 million in Q1 2025.
Financial highlights
Revenue increased to EUR 163.7 million (up 7.9% year-on-year); EBITDA rose to EUR 26.8 million, margin up to 16.4%.
EBIT improved to EUR 14.4 million from EUR -1.3 million; earnings after tax reached EUR 8.9 million.
Free cash flow increased 50.6% to EUR 13.1 million; disciplined CapEx at EUR 7.7 million.
Net financial debt reduced to EUR 81.9 million, leverage ratio at 0.9x; liquidity strong with EUR 101.8 million in cash.
Equity ratio stable at 48.2%.
Outlook and guidance
Full-year 2026 guidance confirmed: high single-digit revenue growth and operating EBITDA around EUR 95 million (before EUR 5 million project costs).
Expectation of continued operational discipline, margin stability, and focus on innovation and cost control.
Demand for cyclical hydraulic hoses remains subdued; medical and mining segments show robust performance.
Elevated uncertainty due to raw material price shocks and geopolitical risks, but confident in ability to pass on cost increases.
Mid-term growth drivers include German infrastructure, EU defense spending, and Ukraine reconstruction.
Latest events from Semperit
- Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference23 Apr 2026 - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025